The global prostatic ablation devices market size was valued at USD 2.2 billion in 2025 and is projected to grow from USD 2.5 billion in 2026 to USD 6.3 billion by 2033, at a CAGR of 14.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 46.4% in 2025. The growth of the prostatic ablation devices industry is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia (BPH), coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function.
The growth of the prostatic ablation devices industry is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia (BPH), coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function. In addition, continuous advancements in image-guided ablation technologies, including focal therapies such as laser ablation, ultrasound ablation, cryotherapy, and irreversible electroporation, are improving treatment precision and accelerating clinical adoption.
The rising prevalence of benign prostatic hyperplasia (BPH) and prostate cancer is a major driver of the market. The growing elderly male population and increasing awareness of prostate health are leading to higher diagnosis and treatment rates worldwide. As more patients seek minimally invasive alternatives that offer faster recovery, fewer complications, and preservation of urinary and sexual function, the demand for advanced prostate ablation devices continues to grow across both BPH and localized prostate cancer indications.
Furthermore, continuous advancements in image-guided ablation technologies are driving growth in the prostate ablation device market by improving procedural precision, treatment planning, and clinical outcomes. The integration of multiparametric MRI (mpMRI), real-time ultrasound, MRI-ultrasound fusion imaging, and robotic navigation enables accurate localization and targeted ablation of prostate lesions while minimizing damage to surrounding healthy tissue. These innovations enhance physician confidence, reduce procedure-related complications, and improve preservation of urinary continence and sexual function.
The development of MRI-guided transurethral ultrasound ablation (TULSA), advanced high-intensity focused ultrasound (HIFU) systems, and image-guided irreversible electroporation (IRE) platforms has expanded treatment options for both benign prostatic hyperplasia (BPH) and localized prostate cancer. Continuous improvements in software, treatment planning algorithms, and real-time monitoring capabilities are expected to support wider clinical adoption and drive sustained demand for advanced prostate ablation devices.
Moreover, the expanding use of focal therapy for localized prostate cancer presents a significant growth opportunity for the prostate ablation device market. Advances in multiparametric MRI, targeted biopsy, and image-guided ablation technologies are improving treatment precision while preserving healthy prostate tissue and reducing treatment-related side effects. As clinical evidence supporting focal therapy continues to grow and more patients seek organ-preserving, minimally invasive treatment options, the demand for advanced prostate ablation devices is expected to increase across hospitals and specialized urology centers.
The growth of the prostatic ablation devices industry is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia (BPH), coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function. In addition, continuous advancements in image-guided ablation technologies, including focal therapies such as laser ablation, ultrasound ablation, cryotherapy, and irreversible electroporation, are improving treatment precision and accelerating clinical adoption.
The rising prevalence of benign prostatic hyperplasia (BPH) and prostate cancer is a major driver of the market. The growing elderly male population and increasing awareness of prostate health are leading to higher diagnosis and treatment rates worldwide. As more patients seek minimally invasive alternatives that offer faster recovery, fewer complications, and preservation of urinary and sexual function, the demand for advanced prostate ablation devices continues to grow across both BPH and localized prostate cancer indications.
Furthermore, continuous advancements in image-guided ablation technologies are driving growth in the prostate ablation device market by improving procedural precision, treatment planning, and clinical outcomes. The integration of multiparametric MRI (mpMRI), real-time ultrasound, MRI-ultrasound fusion imaging, and robotic navigation enables accurate localization and targeted ablation of prostate lesions while minimizing damage to surrounding healthy tissue. These innovations enhance physician confidence, reduce procedure-related complications, and improve preservation of urinary continence and sexual function.
The development of MRI-guided transurethral ultrasound ablation (TULSA), advanced high-intensity focused ultrasound (HIFU) systems, and image-guided irreversible electroporation (IRE) platforms has expanded treatment options for both benign prostatic hyperplasia (BPH) and localized prostate cancer. Continuous improvements in software, treatment planning algorithms, and real-time monitoring capabilities are expected to support wider clinical adoption and drive sustained demand for advanced prostate ablation devices.
- For instance, in April 2026, Profound Medical announced that its TULSA-PRO platform would be featured in multiple presentations at the Society of Interventional Radiology Annual Scientific Meeting 2026. The system combines real-time MRI guidance with directional ultrasound to enable incision-free, personalized prostate ablation with continuous treatment monitoring and verification.
Moreover, the expanding use of focal therapy for localized prostate cancer presents a significant growth opportunity for the prostate ablation device market. Advances in multiparametric MRI, targeted biopsy, and image-guided ablation technologies are improving treatment precision while preserving healthy prostate tissue and reducing treatment-related side effects. As clinical evidence supporting focal therapy continues to grow and more patients seek organ-preserving, minimally invasive treatment options, the demand for advanced prostate ablation devices is expected to increase across hospitals and specialized urology centers.
Global Prostatic Ablation Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global prostatic ablation devices market report based on product /technology, application, end use, and region:Product / Technology Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Radiofrequency (RF) Ablation Device
- High-Intensity Focused Ultrasound (HIFU) Devices
- Cryoablation Devices
- Microwave Ablation (MWA) / Thermotherapy Devices
- Water Vapor Ablation System
- Laser System
- Irreversible Electroporation (IRE)
Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- Benign Prostatic Hyperplasia (BPH)
- Prostate Cancer
- Others
End Use Outlook (Revenue, USD Million/Billion; 2021 - 2033)
- Hospitals
- Ambulatory Surgery Centers
- Specialty Urology Clinics
- Cancer Centers
Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Prostatic Ablation Devices Market Variables, Trends & Scope
Chapter 4. Prostatic Ablation Devices Market: Product / Technology Estimates & Trend Analysis
Chapter 5. Prostatic Ablation Devices Market: Application Estimates & Trend Analysis
Chapter 6. Prostatic Ablation Devices Market: End Use Estimates & Trend Analysis
Chapter 7. Prostatic Ablation Devices Market: Regional Estimates & Trend Analysis by Product / Technology, Application, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Boston Scientific Corporation
- PROCEPT BioRobotics Corporation
- Urologix, LLC.
- EDAP TMS
- Sonablate Corp.
- Insightec
- Profound Medical Inc.
- ProVerum Ltd.
- Francis Medical, Inc.
- AngioDynamics
- Mermaid Medical
- IceCure Medical
